In gene therapy, immunogenicity isn't just a hurdle, it's a make-or-break factor! Whether you are in the early or late stages of development, reliable data specific to your vector is essential to ensure relevance in your vector’s safety profile assessment. Assessing the presence of anti-AAV ... Read more
In AAV gene therapy, safety isn't optional-it's everything. That's why we're proud to introduce a powerful new tool to your immunogenicity toolkit: the AAV Complement Activation Assay. This assay is the first of its kind available on the market, giving you a critical edge in detecting and managing ... Read more
As gene therapy continues to revolutionize modern medicine, the need for robust, scalable tools to evaluate vector performance and immune responses has never been greater. One critical challenge in this field is the detection of neutralizing antibodies (NAbs) against adeno-associated virus (AAV) ... Read more
Gene therapy is transforming the way we can treat many diseases, but immune responses to AAV vectors remain a critical challenge. Whether you're screening for pre-existing immunity, validating your vector, or preparing for regulatory submission, you need reliable, actionable data-and a partner who ... Read more
